Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29


Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors.

Honarvar H, Westerlund K, Altai M, Sandström M, Orlova A, Tolmachev V, Karlström AE.

Theranostics. 2016 Jan 1;6(1):93-103. doi: 10.7150/thno.12766. eCollection 2016.


Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting.

Westerlund K, Honarvar H, Tolmachev V, Eriksson Karlström A.

Bioconjug Chem. 2015 Aug 19;26(8):1724-36. doi: 10.1021/acs.bioconjchem.5b00292. Epub 2015 Jul 6.


Multifunctional Fe5 C2 nanoparticles: a targeted theranostic platform for magnetic resonance imaging and photoacoustic tomography-guided photothermal therapy.

Yu J, Yang C, Li J, Ding Y, Zhang L, Yousaf MZ, Lin J, Pang R, Wei L, Xu L, Sheng F, Li C, Li G, Zhao L, Hou Y.

Adv Mater. 2014 Jun 25;26(24):4114-20. doi: 10.1002/adma.201305811. Epub 2014 Mar 26.


In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment.

Ardeshirpour Y, Chernomordik V, Hassan M, Zielinski R, Capala J, Gandjbakhche A.

Clin Cancer Res. 2014 Jul 1;20(13):3531-9. doi: 10.1158/1078-0432.CCR-13-1826. Epub 2014 Mar 26.


Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.

Rosik D, Thibblin A, Antoni G, Honarvar H, Strand J, Selvaraju RK, Altai M, Orlova A, Eriksson Karlström A, Tolmachev V.

Bioconjug Chem. 2014 Jan 15;25(1):82-92. doi: 10.1021/bc400343r. Epub 2013 Dec 27.


Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.

Zhang JM, Zhao XM, Wang SJ, Ren XC, Wang N, Han JY, Jia LZ.

Br J Radiol. 2014 Jan;87(1033):20130484. doi: 10.1259/bjr.20130484. Epub 2013 Nov 22.


Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V.

J Nucl Med. 2013 Jun;54(6):961-8. doi: 10.2967/jnumed.112.110700. Epub 2013 Mar 25.


In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.

Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A.

Cancer Biother Radiopharm. 2013 Apr;28(3):187-95. doi: 10.1089/cbr.2012.1304. Epub 2013 Mar 5.


Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.

Honarvar H, Jokilaakso N, Andersson K, Malmberg J, Rosik D, Orlova A, Karlström AE, Tolmachev V, Järver P.

Nucl Med Biol. 2013 Apr;40(3):378-86. doi: 10.1016/j.nucmedbio.2012.12.009. Epub 2013 Jan 26.


HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.

Wållberg H, Grafström J, Cheng Q, Lu L, Martinsson Ahlzén HS, Samén E, Thorell JO, Johansson K, Dunås F, Olofsson MH, Stone-Elander S, Arnér ES, Ståhl S.

J Nucl Med. 2012 Sep;53(9):1446-53. doi: 10.2967/jnumed.111.102194. Epub 2012 Aug 7.


Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.

Perols A, Honarvar H, Strand J, Selvaraju R, Orlova A, Karlström AE, Tolmachev V.

Bioconjug Chem. 2012 Aug 15;23(8):1661-70. doi: 10.1021/bc3002369. Epub 2012 Jul 17.


PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.

Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P, Capala J.

J Nucl Med. 2012 Jun;53(6):939-46. doi: 10.2967/jnumed.111.100354. Epub 2012 May 11. Erratum in: J Nucl Med. 2012 Jul;53(7):1169. Omer, Aras [corrected to Aras, Omer].


Optical imaging with her2-targeted affibody molecules can monitor hsp90 treatment response in a breast cancer xenograft mouse model.

van de Ven SM, Elias SG, Chan CT, Miao Z, Cheng Z, De A, Gambhir SS.

Clin Cancer Res. 2012 Feb 15;18(4):1073-81. doi: 10.1158/1078-0432.CCR-10-3213. Epub 2012 Jan 10.


In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.

Ren G, Webster JM, Liu Z, Zhang R, Miao Z, Liu H, Gambhir SS, Syud FA, Cheng Z.

Amino Acids. 2012 Jul;43(1):405-13. doi: 10.1007/s00726-011-1096-7. Epub 2011 Oct 8.


Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.

Tolmachev V, Feldwisch J, Lindborg M, Baastrup B, Sandström M, Orlova A.

Nucl Med Biol. 2011 Jul;38(5):697-706. doi: 10.1016/j.nucmedbio.2010.11.013. Epub 2011 Mar 3.


Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.

Wållberg H, Orlova A, Altai M, Hosseinimehr SJ, Widström C, Malmberg J, Ståhl S, Tolmachev V.

J Nucl Med. 2011 Mar;52(3):461-9. doi: 10.2967/jnumed.110.083592. Epub 2011 Feb 14.


Affibody-based nanoprobes for HER2-expressing cell and tumor imaging.

Gao J, Chen K, Miao Z, Ren G, Chen X, Gambhir SS, Cheng Z.

Biomaterials. 2011 Mar;32(8):2141-8. doi: 10.1016/j.biomaterials.2010.11.053. Epub 2010 Dec 13.


Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.

Tolmachev V, Wållberg H, Sandström M, Hansson M, Wennborg A, Orlova A.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):531-9. doi: 10.1007/s00259-010-1646-3. Epub 2010 Nov 11.


Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging.

Chernomordik V, Hassan M, Lee SB, Zielinski R, Gandjbakhche A, Capala J.

Mol Imaging. 2010 Aug;9(4):192-200.


A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.

Tolmachev V, Velikyan I, Sandström M, Orlova A.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1356-67. doi: 10.1007/s00259-009-1367-7. Epub 2010 Feb 4.


Supplemental Content

Loading ...
Support Center